{
    "relation": [
        [
            "Published Date",
            "Feb 17, 2015",
            "Mar 28, 2014",
            "Sep 10, 2013",
            "Aug 15, 2013",
            "Jul 2, 2013",
            "Jun 4, 2013",
            "Sep 6, 2012",
            "Feb 28, 2011",
            "Sep 14, 2010",
            "Dec 18, 2009",
            "Aug 8, 2007"
        ],
        [
            "Version",
            "16 (current)",
            "15",
            "14",
            "13",
            "12",
            "11",
            "10",
            "9",
            "8",
            "4",
            "1"
        ],
        [
            "Files",
            "download",
            "download",
            "download",
            "download",
            "download",
            "download",
            "download",
            "download",
            "download",
            "download",
            "download"
        ]
    ],
    "pageTitle": "DailyMed - EXELON- rivastigmine patch, extended release",
    "title": "",
    "url": "http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=07c12e14-bbd5-4ec8-84e4-fbe7b5ba10e0",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042986022.41/warc/CC-MAIN-20150728002306-00031-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 63392327,
    "recordOffset": 63341023,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampBeforeTable": "{11528=T2015-28 February 2015, 43789=In Study 1, 1195 patients were randomized to 1 of the following 4 treatments: EXELON PATCH 9.5\u00a0mg/24\u00a0hours, EXELON PATCH 17.4\u00a0mg/24\u00a0hours, EXELON Capsules in a dose of 6\u00a0mg twice daily, or placebo. This 24-week study was divided into a 16-week titration phase followed by an 8-week maintenance phase. In the active treatment arms of this study, doses below the target dose were permitted during the maintenance phase in the event of poor tolerability., 38876=Out of a total of 1584 patients enrolled in the initial open-label phase of the study, 567 patients were classified as decliners and were randomized into the 48-week double-blind treatment phase of the study. Two hundred eighty-seven (287) patients entered the 9.5 mg/24 hours EXELON PATCH treatment group and 280 patients entered the 13.3 mg/24 hours EXELON PATCH treatment group., 148202=Warnings and Precautions (5.1, 5.3) \u00a0\u00a0\u00a0\u00a0\u00a0 2/2015, 148368=Dosage and Administration (2.2, 2.4) \u00a0\u00a0\u00a0\u00a0\u00a0 2/2015, 142761=To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch., 115458=EXELON PATCH has been administered to 4516 patients with Alzheimer\u2019s disease during clinical trials worldwide. Of these, 3005 patients have been treated for at least 26 weeks, 1771 patients have been treated for at least 52 weeks, 974 patients have been treated for at least 78 weeks and 24 patients have been treated for at least 104 weeks., 114216=In Study 1, which randomized a total of 1195 patients, the proportions of patients in the EXELON PATCH 9.5 mg/24 hours, EXELON Capsules 6 mg twice daily, and placebo groups who discontinued treatment due to adverse events were 10%, 8%, and 5%, respectively., 25782=T2015-27 February 2015, 3899=T2015-29 February 2015, 13583=Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088., 141152=Revised: 2/2015, 72823=In patients with dementia associated with Parkinson\u2019s disease the following adverse drug reactions have only been observed in clinical trials with EXELON Capsules: Frequent: nausea, vomiting, decreased appetite, restlessness, worsening of Parkinson\u2019s disease, bradycardia, diarrhea, dyspepsia, salivary hypersecretion, sweating increased; Infrequent (those occurring between 1/100 to 1/1000 patients): dystonia, atrial fibrillation, atrioventricular block., 33912=In this study, 716 patients were randomized into one of the following treatments: EXELON PATCH 13.3 mg/24 hours or EXELON PATCH 4.6 mg/24 hours in a 1:1 ratio. This 24-week study was divided into an 8-week titration phase followed by a 16-week maintenance phase. In the active treatment arms of this study, temporary dose adjustments below the target dose were permitted during the titration and maintenance phase in the event of poor tolerability., 127856=(f) May wear the patch during bathing and in hot weather. But avoid long exposure to external heat sources (excessive sunlight, saunas, solariums).}",
    "textBeforeTable": "Number of versions: 11 EXELON- rivastigmine patch, extended release View Label Archives for this drug View Label Archives, RxNorm, Get Label RSS Feed More Info on this Drug Medline Plus, Clinical Trials, PubMed, Biochemical Data Summary Related Resources Report Adverse Events, FDA Safety Recalls, Presence in Breast Milk Safety (also available in the left menu) Find additional resources Close All Sections View All Sections Close Labeler -\u00a0Novartis Pharmaceuticals Corporation (002147023) 07/06/2007 NDA022083 NDA Marketing End Date Marketing Start Date Application Number or Monograph Citation Marketing Category Marketing Information 24 h in 1 PATCH NDC:0078-0503-61 1 30 in 1",
    "textAfterTable": "RxNorm EXELON- rivastigmine patch, extended release RxCUI RxNorm NAME RxTTY 1 725021 24 HR rivastigmine 0.192 MG/HR Transdermal Patch SCD 2 725021 rivastigmine 0.192 MG/HR 24 HR Transdermal Patch SY 3 725021 rivastigmine 4.6 MG/Day 24 HR Transdermal Patch SY 4 725023 24 HR rivastigmine 0.396 MG/HR Transdermal Patch SCD 5 725023 rivastigmine 0.396 MG/HR 24 HR Transdermal Patch SY 6 725023 rivastigmine 9.5 MG/Day 24 HR Transdermal Patch SY 7 725105 24 HR rivastigmine 0.396 MG/HR Transdermal Patch [Exelon] SBD 8 725105 Exelon 0.396 MG/HR 24 HR Transdermal Patch SY 9 725105 Exelon 9.5 MG/Day 24 HR Transdermal Patch SY 10 751302 24 HR rivastigmine 0.192 MG/HR Transdermal Patch [Exelon] SBD 11 751302 Exelon 0.192 MG/HR 24HR Transdermal Patch SY 12 751302 Exelon 4.6 MG per 24HR 1 Day Transdermal Patch SY 13 1308569 24 HR rivastigmine 0.554 MG/HR Transdermal Patch SCD 14 1308569 rivastigmine 13.3 MG/Day 24HR Transdermal Patch SY 15 1308571 24 HR rivastigmine 0.554 MG/HR Transdermal Patch [Exelon] SBD 16 1308571 24 HR Exelon 0.554 MG/HR Transdermal Patch SY",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}